Article

Use of anti-secretory medication: a population-based cohort study

Department of Medical Gastroenterology, Odense University Hospital, Odense C, Denmark.
Alimentary Pharmacology & Therapeutics (Impact Factor: 5.48). 10/2004; 20(5):577-83. DOI: 10.1111/j.1365-2036.2004.02120.x
Source: PubMed

ABSTRACT Total use of anti-secretory medication (H2 blockers and proton pump inhibitors) is increasing rapidly, but knowledge of factors related to the increasing use is sparse.
To describe development in the use of anti-secretory medication between 1993 and 2002 at a population level.
We extracted data on use of anti-secretory medication (H2-blockers and proton pump inhibitors) and ulcerogenic drugs, demographic data, and data on gastroscopy and endoscopically verified oesophagitis and peptic ulcer diagnoses, from three large population-based databases covering the County of Funen, Denmark 1990-2002 (population 470,000).
Between 1993 and 2002 incidence of first time users was stable at 16.7/1000 persons/year. Total amount of consumed anti-secretory medication increased from 10.5 DDD/1000 persons/day to 25.2 DDD/1000 persons/day. Ninety per cent of the increase was related to long-term use of anti-secretory medication (> or = 180 DDD/patient/year). In 1993 21% of the anti-secretory medication was used by patients with oesophagitis, this increased to 28% in 2002. The proportion of medication used by peptic ulcer patients decreased from 29% in 1993 to 19% in 2002.
Total use of anti-secretory medication increased as a result of more extensive long-term use, and most of the medication was used by patients without diagnosed peptic ulcer or oesophagitis.

0 Followers
 · 
76 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: El modelo homeopático considera la acción secundaria o la reacción vital del organismo como un método terapéutico y, por lo tanto prescribe tratamientos por el principio de similitud; éste consiste en administrar a los individuas enfermos sustancias que han causado síntomas similares en individuas sanas. La reacción vital homeostática o paradójica de un organismo puede ser explicada científicamente en base al efecto de rebate de los medicamentos modernos, el cual puede causar eventos iatrogénicos fatales posteriores a la suspensión de un tratamiento antipático (un término utilizado en medicina alternativa para el tratamiento paliativo, también conocido como enantiopático). Aunque el efecto de rebate ha sido estudiado por la farmacología moderna, este ha sido poco difundido y discutido entre los profesionales de la salud, quienes en muchas ocasiones han sido privados de información crucial necesaria para el manejo seguro de los medicamentos actuales. En este artículo se presenta una revisión actual sobre el efecto de rebate de los medicamentos modernos que fundamentan el principio homeopático de curación y alerta a los médicos sobre este tipo de efecto adverso que usualmente no se notifica. EI efecto de rebate de los medicamentos modernos paliativos fue señalado por Hahnemann hace más de dos siglas, mencionando que éste puede causar efectos adversos fatales, los cuales pueden ser evidenciados como en el caso del ácido acetilsalicílico, los agentes antiinflamatorios, antidepresivos, broncodilatadores, las estatinas, los inhibidores de la bomba de protones, etc. Aunque el efecto de rebate solamente se presenta en una pequeña fracción de individuas (susceptibles) y puede ser evitado mediante una disminución gradual de los medicamentos antipáticos, este ha de mostrado una importancia epidemiológica significativa como resultado del uso masivo de tales drogas paliativas y la falta de conocimiento a este respecto.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The homeopathic model applies the secondary action or vital reaction of the organism as a therapeutic method and thus prescribes treatment by similitude, which consists in administering to ill individuals substances that cause similar symptoms in healthy individuals. The vital, homeostatic or paradoxical reaction of the organism might be explained scientifically by means of the rebound effect of modern drugs, which might cause fatal iatrogenic events after discontinuation of antipathic (a term used in alternative medicine for palliative treatment, also known as enantiopathic) treatment. Although the rebound effect is studied by modern pharmacology, it is poorly communicated to and discussed among healthcare professionals, who are thus deprived of information needed for the safe management of modern drugs. This article presents an up-to-date review on the rebound effect of modern drugs that grounds the homeopathic principle of healing and calls the attention of doctors to this type of adverse effect that is usually unnoticed. The rebound effect of modern palliative drugs, which was pointed out by Hahnemann more than two centuries ago, might cause fatal adverse events and is illustrated by the examples of acetylsalicylic acid, anti-inflammatory agents, bronchodilators, antidepressants, statins, proton-pump inhibitors, etc. Although the rebound effect is expressed by a small fraction of (susceptible) individuals and might be avoided by gradual tapering of antipathic drugs, it exhibits epidemiologic importance as a function of the massive use of such palliative drugs and the lack of knowledge in its regard.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Objective. Both over-the-counter medicine, such as antacids or alginates, and proton pump inhibitors (PPI) are used for treating acid-related disorders. We sought to describe what characterizes users of these different medicines, including long-term PPI users within the general population. Method. A cross-sectional survey was conducted in an internet panel representative of the Danish adult population in 2012. Data queried included antacid/alginate and PPI use, reason for therapy, co-medication, and presence of upper gastrointestinal symptoms. Long-term PPI use was defined as using PPI ≥1/3 of the last year (∼120 days). Risk of long-term PPI use was estimated by logistic regression. Results. A total of 18,223 people received the questionnaire, of which 52% (9390) responded. Antacid/alginate use was reported by 23%; 16% reported use of only antacid/alginate. PPI use was reported by 13.6%; 6.2% were defined as long-term PPI users. Antacid/alginate users were younger, used less co-medication, had most often started on therapy because of reflux symptoms, and had less often ongoing symptoms. Risk of long-term PPI use appeared to be increased in male gender, by renewing PPI prescription by phone/e-mail, using co-medication, and having started on PPI for several reasons. Combination of antacid/alginate and PPI was reported by approximately 50% of those on therapy with weekly or daily symptoms. Conclusion. 23% of Danish adults were using antacids or alginates and 14% were using PPI, of which one-half were on long-term therapy. Prescription renewal by phone or e-mail and use of other prescription medication were associated with long-term PPI use, indicating a behavioral pattern, in which unnecessary PPI therapy may be maintained.
    Scandinavian Journal of Gastroenterology 05/2014; DOI:10.3109/00365521.2014.923504 · 2.33 Impact Factor

Preview

Download
0 Downloads